Download PDF

1. Company Snapshot

1.a. Company Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.


It also offers ELISA test kits; and chromatography resins under the CaptivA brand.In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber.Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands.


The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations.Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands.Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Show Full description

1.b. Last Insights on RGEN

Repligen Corporation's recent performance was negatively impacted by a series of institutional investor transactions, including AWM Investment Company Inc.'s 21.1% reduction in shares and Bessemer Group Inc.'s 95.2% decrease in holdings. Additionally, Edgestream Partners L.P. made a new $3.48 million investment in the company, while Assenagon Asset Management S.A. and Delta Investment Management LLC purchased new positions in Repligen.

1.c. Company Highlights

2. Disappointing EPS, Strong Revenue Growth

The company's fourth quarter revenue reached $198 million, representing 14% organic growth, and $738 million for the full year, exceeding the high end of the October guidance for both revenue and adjusted operating income. The adjusted gross profit was $104 million in the fourth quarter, with an adjusted gross margin of 52.4%, expanding 170 basis points versus last year. However, the actual EPS came out at $0.49, which is higher than the same period in 2024, but analysts' estimates were not found, yet the reported $0.49 is higher than the '0.44' estimate mentioned. For the full year, the company delivered $1.71 of adjusted fully diluted earnings per share, up 9% over last year.

Publication Date: Feb -25

📋 Highlights
  • Revenue Growth:: Q4 revenue reached $198M (+14% organic), with FY2025 at $738M (+14% organic), exceeding guidance high-end for revenue and adjusted operating income.
  • Segment Performance:: Proteins/Process Analytics grew >30%, Chromatography >25%, and Filtration high single digits in Q4; Analytics drove 37% full-year growth.
  • 2026 Guidance:: Revenue $810M–$840M (9%–13% organic growth), 150 bps operating margin expansion, with adjusted gross margin targeting 53.6%–54.1% (+125 bps at midpoint).
  • Margin Expansion:: FY2025 adjusted operating margin hit 13.8% (+90 bps YoY); adjusted operating income rose 24% to $102M, with adjusted net income up $3M to $28M.
  • EPS & Cash Position:: Q4 adjusted EPS $0.49 (+11% YoY); FY2026 guidance of $1.93–$2.01 EPS (+15% at midpoint). Cash/marketable securities at $768M as of Q4 2025.

Segment Performance

The diversified portfolio performed well, with Proteins and Process Analytics growing over 30% and Chromatography growing over 25%. Filtration grew high single digits for the quarter and the year, driven by Consumables. The company's initial 2026 guidance calls for $810 million to $840 million of revenue or 9% to 13% organic revenue growth, with Proteins growing low double-digit, Chromatography growing low double-digit, and Analytics growing greater than 20%.

Guidance and Outlook

The company is guiding $810 million to $840 million of revenue or 10% to 14% reported growth and 9% to 13% on an organic basis for 2026. Analysts estimate next year's revenue growth at 14.8%, indicating a slightly higher growth expectation. The adjusted operating margin is expected to expand by 150 basis points at the midpoint, driven by good gross margin expansion, volume leverage, and OpEx management.

Valuation Metrics

With a P/E Ratio of 156.6 and an EV/EBITDA of 47.66, the company's valuation appears to be high, indicating that the market has already priced in significant growth expectations. The ROE of 2.36% and ROIC of 1.68% suggest that the company's profitability is relatively low. The Net Debt / EBITDA ratio of 0.77 indicates a manageable debt level.

Future Focus

The company is focusing on executing its strategy, driving above-market revenue growth, and balancing margin expansion with investments in the business. With a strong balance sheet and a focus on innovation, the company is well-positioned to deliver growth in 2026, with several new products in the pipeline, including a combination of ATF with Raman technology and a new Mid-IR technology.

3. NewsRoom

Card image cap

Repligen Corporation $RGEN Stock Position Raised by Congress Asset Management Co.

Mar -24

Source: defenseworld.net

Card image cap

Repligen Conference: CEO touts differentiated bioprocessing portfolio; CFO targets 30% EBITDA margin

Mar -23

Source: defenseworld.net

Card image cap

Repligen Corporation (RGEN) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

Mar -18

Source: seekingalpha.com

Card image cap

Cinctive Capital Management LP Takes Position in Repligen Corporation $RGEN

Mar -16

Source: defenseworld.net

Card image cap

Repligen Corporation (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Mar -13

Source: defenseworld.net

Card image cap

Repligen Corporation (RGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar -10

Source: seekingalpha.com

Card image cap

Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y

Feb -25

Source: zacks.com

Card image cap

Repligen Corporation (RGEN) Q4 2025 Earnings Call Transcript

Feb -24

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.58%)

6. Segments

Filtration

Expected Growth: 10%

Repligen's Filtration segment growth is driven by increasing bioprocessing demand, adoption of single-use technologies, and expanding biologics pipelines. The company's chromatography and filtration products are critical components in biomanufacturing, supporting the development of novel therapies and vaccines. Strong demand from biotech and pharma companies, coupled with Repligen's innovative products and strategic acquisitions, contribute to the segment's 10% growth.

Chromatography

Expected Growth: 11%

Repligen's Chromatography segment growth is driven by increasing bioprocessing demand, adoption of single-use technologies, and expansion in emerging markets. The 11% growth rate is also fueled by the company's strategic acquisitions, innovative product offerings, and strong relationships with key biopharmaceutical customers.

Proteins

Expected Growth: 13%

Repligen Corporation's 13% growth in proteins is driven by increasing demand for bioprocessing technologies, expansion into new markets, and strategic partnerships. The company's chromatography and filtration products are benefiting from the growing need for high-quality biologics. Additionally, Repligen's focus on single-use technologies and its ability to provide customized solutions are contributing to its growth momentum.

Process Analytics

Expected Growth: 9%

Repligen's Process Analytics segment growth is driven by increasing adoption of single-use technologies, rising demand for bioprocess monitoring and control, and expansion into new markets such as cell and gene therapy. Additionally, strategic acquisitions and partnerships have enhanced the company's offerings, contributing to the 9% growth rate.

Other Product

Expected Growth: 8%

Repligen's Other Products segment, with 8% growth, is driven by increasing demand for bioprocessing technologies, expansion into new markets, and strategic partnerships. The company's chromatography and filtration products are experiencing high adoption rates, while its single-use assemblies and systems are benefiting from the trend towards single-use bioprocessing. Additionally, Repligen's investments in R&D and manufacturing capacity are supporting the growth of this segment.

Royalty and Other

Expected Growth: 7%

Repligen Corporation's 7% growth in Royalty and Other is driven by increasing demand for bioprocessing technologies, expansion of existing partnerships, and new licensing agreements. Additionally, the company's strategic investments in gene therapy and biologics manufacturing are contributing to revenue growth.

7. Detailed Products

Chromatography Columns

Repligen's chromatography columns are used for the purification of biomolecules, including proteins, antibodies, and vaccines.

Protein A Resins

Repligen's Protein A resins are used for the capture and purification of antibodies and other biomolecules.

TFF Systems

Repligen's Tangential Flow Filtration (TFF) systems are used for the concentration and diafiltration of biomolecules.

XCell ATF Systems

Repligen's XCell ATF systems are used for the continuous clarification and concentration of cell culture broths.

Filtration Systems

Repligen's filtration systems are used for the clarification and sterilization of biopharmaceuticals.

Biosimilarity Analysis

Repligen's biosimilarity analysis services are used to compare the structure and function of biosimilars to their reference products.

8. Repligen Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Repligen Corporation's products are highly specialized and customized, making it difficult for substitutes to emerge. However, the company's reliance on a few key customers and suppliers increases the threat of substitutes.

Bargaining Power Of Customers

Repligen Corporation's customers are large pharmaceutical and biotechnology companies with significant bargaining power. They can negotiate prices and terms, which can negatively impact the company's revenue and profitability.

Bargaining Power Of Suppliers

Repligen Corporation has a diverse supplier base, which reduces the bargaining power of individual suppliers. The company's strong relationships with suppliers also help to mitigate the risk of supply chain disruptions.

Threat Of New Entrants

The bioprocessing industry has high barriers to entry, including significant capital expenditures and regulatory hurdles. This makes it difficult for new entrants to compete with established players like Repligen Corporation.

Intensity Of Rivalry

The bioprocessing industry is highly competitive, with several established players competing for market share. However, Repligen Corporation's strong brand reputation and customer relationships help to mitigate the intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 22.89%
Debt Cost 3.95%
Equity Weight 77.11%
Equity Cost 9.08%
WACC 7.90%
Leverage 29.69%

11. Quality Control: Repligen Corporation passed 6 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Merit Medical Systems

A-Score: 4.2/10

Value: 2.7

Growth: 7.3

Quality: 5.3

Yield: 0.0

Momentum: 2.5

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
DENTSPLY SIRONA

A-Score: 4.2/10

Value: 7.3

Growth: 1.6

Quality: 2.8

Yield: 7.0

Momentum: 1.0

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
Teleflex

A-Score: 3.7/10

Value: 6.2

Growth: 3.4

Quality: 5.1

Yield: 1.0

Momentum: 1.0

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Repligen

A-Score: 3.6/10

Value: 0.4

Growth: 5.0

Quality: 5.1

Yield: 0.0

Momentum: 7.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Azenta

A-Score: 3.3/10

Value: 5.1

Growth: 4.4

Quality: 4.8

Yield: 0.0

Momentum: 2.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Cooper

A-Score: 3.2/10

Value: 2.6

Growth: 2.0

Quality: 5.8

Yield: 0.0

Momentum: 2.0

Volatility: 6.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

111.19$

Current Price

111.19$

Potential

-0.00%

Expected Cash-Flows